Join
Live feed
·
INSIDERFilingvia Quantisnow
Relay Therapeutics Inc. logo

President and CEO Patel Sanjiv was granted 3,056 shares and sold $943,736 worth of shares (48,199 units at $19.58) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 615,898 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RLAY· Relay Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLAY (Relay Therapeutics Inc.) and more on Quantisnow.